Here's the one thing people are forgetting. Afrezza, as far as I know, isn't trying to corner the market on insulin for diabetics. From what I can discern, Afrezza will be something to help supplement Diabetics. In some cases, Afrezza might be the only insulin a person might need. But, there are niches to Afrezza that could make it the only game in town, like pre-diabetics, etc. And if Afrezza is really that easy to use, the ability to whip it out, suck it in and have it act quickly surely beats any injection, even if one doesn't feel anything.

There will be aplace for this in treating diabetes. Obviously, Afrezza needs to get FDA approval, but the question is how much penetration will Afrezza get? Will Doctors be able to put Exubera aside and actually Rx this to their patients to try? The key is the marketing of this. And that's where MNKD might fail miserably.